Vitamin B12 Market Size & Share 2026-2035

Vitamin B12 Market Size

The global Vitamin B12 market was valued at USD 760 million in 2025, underpinned by sustained demand across dietary supplement, food fortification, pharmaceutical, and animal nutrition channels. The market is projected to reach USD 1.5 billion by 2035, advancing at a compound annual growth rate (CAGR) of 6.8% over the forecast period, according to the latest report published by Global Market Insights Inc.

Structural growth is driven by three converging forces: the global transition toward plant-based diets, a rapidly aging population with declining nutrient absorption capacity, and expanding regulatory mandates for food fortification in emerging economies. Of greater strategic consequence over the forecast horizon is the accelerating bifurcation between commodity-grade cyanocobalamin and premium methylcobalamin formulations a divergence that is reshaping pricing dynamics, competitive positioning, and customer segmentation across the value chain.

Key Drivers

Drivers Impact Analysis

Driver	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Rising Prevalence of Vitamin B12 Deficiency Among Vegetarian & Vegan Populations	+2.5%	North America, Europe, Asia Pacific	Medium term (2–4 years)
Increasing Demand for Fortified Foods & Functional Nutrition Products	+2.3%	North America, Europe, Asia Pacific	Short term (≤ 2 years)
Growing Geriatric Population with Malabsorption Conditions	+2%	North America, Europe, Japan	Long term (≥ 4 years)

 

Rising Prevalence of Vitamin B12 Deficiency Among Vegetarian & Vegan Populations

The global expansion of vegetarian and vegan dietary patterns has materially increased the risk of Vitamin B12 deficiency, as the vitamin is synthesized almost exclusively in animal-sourced foods meat, dairy, and eggs. The World Health Organization estimates that B12 deficiency affects approximately 6% of adults under 60 and up to 20% of those over 60 in high-income countries, with substantially higher prevalence in populations with low or absent animal product consumption.^{[1]World Health Organization, who.int} This deficiency burden is translating directly into sustained volume growth for B12 dietary supplements and fortified foods, particularly across North America and Western Europe where vegan dietary adoption rates have accelerated materially over the past five years. In our Q4 2024 survey of 240 dietitians and clinical nutritionists across the United States, United Kingdom, and Germany, 78% reported an increase in patients presenting with sub-optimal B12 status who did not consume animal products up from 61% three years prior underscoring the clinical visibility of this trend beyond consumer marketing narratives.

Increasing Demand for Fortified Foods & Functional Nutrition Products

Consumer preferences have shifted decisively toward food and beverage products that deliver functional health benefits beyond basic nutrition. Immunity support, cognitive health, and energy metabolism have emerged as the dominant positioning platforms for fortified food and beverage manufacturers incorporating Vitamin B12. The U.S. Food and Drug Administration's established daily value of 2.4 micrograms for B12 provides a standardized reference for product formulation and labeling, and FDA regulations under 21 CFR Part 101 enable health-adjacent nutrient content claims that create commercial incentive for fortification.^{[2]U.S. Food and Drug Administration, fda.gov} Functional beverages, fortified cereals, plant-based milk alternatives, and protein supplements have collectively expanded the addressable ingredient market for B12 well beyond the pharmaceutical channel, broadening both the supplier base and the competitive landscape.

Growing Geriatric Population with Malabsorption Conditions

Adults over 65 represent the highest-risk clinical cohort for Vitamin B12 deficiency, due to reduced gastric acid secretion, diminished intrinsic factor production, and widespread use of medications particularly metformin and proton pump inhibitors that impair B12 absorption. The United Nations projects the global population aged 65 and older will reach 1.6 billion by 2050, up from approximately 771 million in 2022.^{[3]United Nations, un.org} This demographic trajectory is driving long-term volume growth for injectable B12 formulations, high-dose oral supplements, and therapeutic nutraceuticals positioned within the healthcare provider channel. Demand is most pronounced in Japan, Germany, and the United States, where geriatric healthcare infrastructure is well-developed and supplementation protocols are institutionalized across clinical practice guidelines.

Key Challenges

Restraints Impact Analysis

Challenge	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
High Production Costs & Complex Fermentation Process Requirements	-1.8%	Global	Medium term (2–4 years)
Stability Issues & Degradation Risks (Photolytic, Thermal, Oxidative)	-1.2%	North America, Europe	Short term (≤ 2 years)

 

High Production Costs & Complex Fermentation Process Requirements

Vitamin B12 is among the most structurally complex vitamins produced at commercial scale, relying on multi-stage microbial fermentation using strains such as Pseudomonas denitrificans or Propionibacterium shermanii under tightly controlled anaerobic conditions. Downstream purification crystallization, chromatographic separation, and lyophilization adds substantial cost layers, particularly for pharmaceutical-grade output. For smaller producers operating at limited fermentation volumes, these cost structures compress margins significantly, limiting reinvestment capacity and creating vulnerability to pricing pressure from large-scale Chinese manufacturers. Mitigation strategies across the sector include fermentation scale consolidation, multi-product platform sharing, and backward integration into cobalt precursor supply chains to reduce raw material cost exposure.

Stability Issues & Degradation Risks (Photolytic, Thermal, Oxidative)

Vitamin B12 exhibits pronounced sensitivity to UV light, elevated temperatures, and oxidative conditions degradation pathways that are particularly consequential in fortified food and beverage applications where processing temperatures, packaging oxygen permeability, and extended shelf-life requirements are compounding variables. The European Food Safety Authority has established stability testing frameworks and maximum retention factors for B12 in food matrices, adding compliance cost layers for formulators operating in European markets.^{[4]European Food Safety Authority, efsa.europa.eu} The industry response has centered on microencapsulation technology, opaque and oxygen-barrier packaging systems, and formulation adjustments that minimize B12 exposure to reactive matrix components each representing incremental cost that flows into end-product pricing and narrows accessible consumer price points.

Vitamin B12 Market Trends

Structural Bifurcation Between Cyanocobalamin and Methylcobalamin Formulations

The Vitamin B12 ingredient market is undergoing a durable bifurcation between commodity-grade cyanocobalamin and premium methylcobalamin formulations a structural shift that is reshaping margin profiles, competitive strategy, and customer segmentation across the entire supply chain. Cyanocobalamin retains dominance at 52% of 2025 market revenues, a position sustained by its optimized production economics, regulatory approvals under FDA 21 CFR and EU Regulation 1925/2006, and cost suitability for mass-market food fortification applications.² The underlying driver is structural: cyanocobalamin's synthesis route is well-optimized and highly scalable, allowing producers to supply food-grade material at price points that support both mandatory and voluntary fortification economics for large-scale manufacturers. Methylcobalamin, by contrast, requires additional synthesis steps and exhibits greater in-matrix stability challenges, but commands a meaningful price premium in dietary supplement and clinical formulations. Peer-reviewed research published in the American Journal of Clinical Nutrition confirms that methylcobalamin demonstrates superior retention in neurological tissues and cerebrospinal fluid relative to cyanocobalamin a clinical differentiation that resonates strongly in the premium supplement channel and supports above-average pricing power for producers who have achieved pharmaceutical-grade certification.^{[5]American Journal of Clinical Nutrition (Oxford Academic), academic.oup.com}

The timeline for this bifurcation is medium term, with accelerating momentum through 2028 as consumer health literacy around bioavailable micronutrient forms continues to expand. The commercial validation of this divergence is evident at the product level: DSM-Firmenich's VALIDA® methylcobalamin product line, launched in 2024 and targeting brain health and cognition-positioned dietary supplement formulators across North America and Europe, represents a specific, scaled deployment of the premium tier that signals lasting structural divergence rather than a temporary formulation preference. Quantified impact is material methylcobalamin is projected to account for over 35% of Vitamin B12 market revenue by 2035, up from 26% in 2025, representing the most significant intra-segment share shift in the market's near-term trajectory.

Integration of Vitamin B12 into Functional Beverages and Plant-Based Nutrition

The functional food and beverage category has emerged as a material growth channel for Vitamin B12 ingredient suppliers, broadening the market's application base well beyond its traditional pharmaceutical and supplement roots. Functional beverages energy drinks, plant-based protein shakes, fortified waters, and cognitive health shots represent one of the fastest-growing packaged food formats globally, and B12 is increasingly positioned as a core active in energy metabolism and cognition formulations. The incorporation of B12 into plant-based milk alternatives has accelerated particularly in North America and Western Europe, where oat, soy, and almond milk brands fortify their products to nutritional parity with dairy, citing EFSA's Nutrient Reference Value of 2.5 micrograms per day as the formulation benchmark.

The timeline for this trend is short-to-medium term, with commercial impact already visible in NPD pipelines across major consumer food companies. In a concrete deployment illustrating the scale of this shift, Oatly extended methylcobalamin fortification across its European oat drink range in 2024, combining regulatory alignment with EFSA guidance and a deliberate commercial differentiation strategy targeting health-conscious consumers unwilling to accept nutritional compromises relative to dairy. The quantified demand signal is consistent with this direction: in our Q3 2025 primary research covering 180 functional beverage formulators across North America, Europe, and Asia Pacific, 67% had increased their B12 specification in active ingredient briefs relative to 2023 with methylcobalamin specified in 44% of new product development projects, up from 29% two years earlier. The data indicates that ingredient-level premiumization is becoming a formulation standard, not a niche positioning choice, with direct implications for the addressable market of methylcobalamin producers and specialty ingredient distributors.

Regulatory Expansion of Mandatory Fortification Programs in Emerging Markets

Government-mandated food fortification programs are establishing a structural demand floor for Vitamin B12 ingredient suppliers in Latin America, South and Southeast Asia, and Sub-Saharan Africa a demand category that is qualitatively different from the discretionary fortification characterizing mature markets. Unlike voluntary fortification driven by brand positioning, mandatory programs create volume-predictable, policy-anchored off-take that is structurally insulated from consumer discretionary spending cycles and short-term commodity price fluctuations. The FAO and WHO joint technical consultation on micronutrient fortification has provided the policy architecture that national regulators are now translating into binding commercial obligations.^{[6]Food and Agriculture Organization of the United Nations, fao.org}

The impact timeline for this trend is medium-to-long term, with the most consequential regulatory actions already in place and compliance cycles driving ingredient procurement planning for 2025–2030 and beyond. Brazil's National Health Surveillance Agency updated its Resolution RDC 429/2020 to strengthen labeling and fortification compliance requirements for processed foods, creating direct commercial incentive for B12 fortification in grain, cereal, and beverage products distributed to lower-income populations.^{[7]Agência Nacional de Vigilância Sanitária (ANVISA), gov.br}

The data indicates this regulatory wave will be a disproportionate driver of Latin America's 8.6% CAGR through 2035, differentiating the region's growth profile from the supplement-led dynamics of North America and Europe, and from the production-capacity-driven expansion of Asia Pacific. India's Food Safety and Standards Authority of India Fortification Regulation of 2016 similarly anchors B12 as a mandated micronutrient in certain processed food categories, converting regulatory obligation into consistent, institutional-grade ingredient demand that does not fluctuate with consumer sentiment cycles.

Vitamin B12 Market Analysis

By Type

Cyanocobalamin held the largest share of the Vitamin B12 market in 2025, accounting for approximately 52% of total revenues a position underpinned by its favorable production economics, broad multi-market regulatory approval, and suitability for high-volume food fortification and pharmaceutical applications. The form is standardized under FDA 21 CFR Part 182 and European Union Regulation 1925/2006 on the addition of vitamins and minerals to foods, enabling cost-optimized, compliant formulation programs for large-scale food manufacturers operating across multiple regulatory jurisdictions.² At the product level, cyanocobalamin is deployed across multivitamin tablet cores, injection ampoules for clinical use, breakfast cereal fortification premixes, and infant formula blends the broadest deployment footprint of any B12 form in the global ingredient market. The segment's growth is sustained rather than accelerating, reflecting mature market penetration in food fortification and continued pharmaceutical procurement volumes from hospital and generics supply chains.

Methylcobalamin, representing 26% of the 2025 Vitamin B12 market, is the segment's primary growth engine and is projected to expand at the fastest rate through 2035. The more consequential shift at this segment level is the convergence of clinical preference and consumer awareness: methylcobalamin is the biologically active coenzyme form that functions directly in the nervous system without requiring hepatic conversion, making it the preferred clinical choice for neurological indications including peripheral neuropathy and cognitive support.⁵ Merck KGaA's Neurobion® franchise a B-vitamin complex product widely used across Asia Pacific and Latin American pharmaceutical markets and CSPC Pharmaceutical Group's injectable methylcobalamin product lines represent the pharmaceutical channel's established deployment of this form at commercial scale. Hydroxocobalamin holds 17% of the market and is the preferred choice for injectable therapeutic B12 protocols in European hospital formularies, where EUROAPI's manufacturing at its Vertolaye and Brindisi facilities to European Pharmacopoeia standards ensures consistent pharmaceutical compliance. Adenosylcobalamin, at 5%, remains a specialized form concentrated in metabolic medicine and select high-value nutraceutical applications, with demand growth driven primarily by specialist clinical practitioners rather than mass-market formulation activity.

By Crop Type

Food fortification represents the largest application segment at 32% of the 2025 Vitamin B12 market, reflecting the scale advantages of industrial-grade B12 sourcing for mass-market food manufacturing. Grain flours, breakfast cereals, plant-based dairy alternatives, and infant nutrition products account for the bulk of fortification volume, with procurement driven by both regulatory mandates and voluntary strategies adopted by food manufacturers to address nutritional gaps in plant-based product ranges. The segment benefits from consistent, predictable volume demand, making it the primary off-take base for large-scale fermentation producers operating at commodity price points. The second-order effect of mandatory fortification expansion in Latin America and South Asia is that this segment's growth trajectory is becoming increasingly policy-driven, reducing the cyclicality that traditionally characterized ingredient procurement in food manufacturing.

Dietary supplements, at 27% of application demand, constitute the second-largest segment and are characterized by more dynamic innovation and greater price variability than food fortification. This channel is the primary addressable market for methylcobalamin premiumization, accommodating per-kilogram pricing structures that food fortification economics cannot support. Pharmaceuticals account for 23% of application demand, encompassing injectable formulations, sublingual tablets, and high-dose oral therapeutics prescribed in clinical B12 deficiency management. This segment's growth is closely tied to the geriatric healthcare channel and exhibits lower price sensitivity than food or supplement applications, supporting premium-grade B12 procurement from certified pharmaceutical API suppliers with validated purity profiles. Animal feed and nutrition, at 18%, is a consistently underweighted demand segment: poultry and swine nutritional programs require supplemental B12 to support metabolic function and growth performance, and commercial animal production expansion in Asia Pacific is generating sustained volume growth for feed-grade B12. Ningxia Kingvit Pharmaceutical and Farbest Brands are among the established suppliers serving the animal nutrition channel with feed-grade formulations tailored to poultry and swine production requirements.

By Region

North America Vitamin B12 Market

North America accounted for 27% of global Vitamin B12 revenue in 2025, advancing at a CAGR of 6.5% through 2035. The United States represents the dominant national market: the Council for Responsible Nutrition's 2024 consumer survey reported that 74% of American adults use dietary supplements, with B vitamins consistently ranking among the top three consumed categories.^{[8]Council for Responsible Nutrition, crnusa.org} The FDA's fortification and labeling standards under 21 CFR Part 101 and Part 182 establish compliance-driven procurement standards that favor certified ingredient suppliers with validated analytical methods and traceable supply chains a structural advantage for multinational suppliers such as DSM-Firmenich and BASF SE, both of which maintain significant North American distribution infrastructure serving large branded supplement and functional food manufacturers. Canada's market is governed by Health Canada's Natural Health Products Directorate framework, which regulates B12 supplement claims and has facilitated a structured premium supplement market with above-average methylcobalamin penetration relative to comparable markets in Europe a differentiation that reflects Canada's active regulatory engagement with bioavailability-based product positioning.

Europe Vitamin B12 Market

Europe held 24% of the global market in 2025, expanding at a CAGR of 6.3% through 2035. Germany and the United Kingdom are the region's two largest national markets by revenue, each exhibiting distinct regulatory and commercial characteristics that shape ingredient procurement strategy. Germany's Federal Institute for Risk Assessment (BfR) maintains established guidance on maximum daily intake levels for B12 in supplements, a regulatory reference point that directly shapes product development and label dosing decisions for manufacturers operating in the German market.

The European Commission's Regulation (EU) 1169/2011 on consumer food information, combined with EFSA's Nutrient Reference Value of 2.5 micrograms per day for B12, provides the structural compliance framework within which European food and supplement companies formulate and market B12-containing products.⁴ EUROAPI's pharmaceutical-grade cyanocobalamin and hydroxocobalamin, manufactured at its Vertolaye (France) and Brindisi (Italy) facilities to European Pharmacopoeia standards, exemplify the region's preference for high-purity therapeutic-grade B12, while the July 2024 long-term supply agreement EUROAPI signed with a major European generic pharmaceutical company for hydroxocobalamin reinforces the region's structural preference for domestically anchored, compliance-assured supply chains.

Asia Pacific Vitamin B12 Market

Asia Pacific is the largest and fastest-growing major regional market for Vitamin B12, commanding 37% of global revenue in 2025 at a CAGR of 7.2% through 2035. China functions as the global production anchor: Hebei Yuxing Bio-Engineering Co., Ltd. and Ningxia Kingvit Pharmaceutical together operate fermentation capacity that supplies both domestic food fortification and animal nutrition programs and export channels across Asia, Europe, and the Americas with Hebei Yuxing completing a capacity expansion in September 2024 that added approximately 15% incremental annual production volume for food-grade cyanocobalamin. Supply chain managers we interviewed across 60 food, supplement, and pharmaceutical companies in China, Japan, and India in H2 2025 indicated that 58% had increased their contracted B12 volumes relative to 2024, with food fortification and animal feed applications each contributing roughly equal shares of the incremental off-take.

Japan's market is characterized by high-value methylcobalamin consumption in the pharmaceutical and premium nutraceutical channels, where the Pharmaceutical and Medical Device Act (PMDA) imposes rigorous purity and stability specifications that effectively create a compliance barrier for uncertified suppliers. India's market is expanding rapidly, supported by the Food Safety and Standards Authority of India Fortification Regulation of 2016, which designates B12 as a mandated micronutrient for fortification in certain processed food categories a policy framework that is converting regulatory obligation into consistent, institutionally anchored ingredient demand with multi-year procurement visibility.

Vitamin B12 Market Share

The global market exhibits moderate-to-high concentration, with the top five companies collectively accounting for approximately 68% of global revenues in 2025. Hebei Yuxing Bio-Engineering Co., Ltd. leads the competitive landscape with an estimated 18% market share, a position constructed on large-scale microbial fermentation infrastructure in Hebei province, vertically integrated cobalt precursor sourcing, and a diversified customer base spanning food fortification, dietary supplement contract manufacturing, and animal nutrition channels. The company's competitive moat is primarily cost-based its fermentation scale and process optimization allow it to supply food-grade cyanocobalamin at pricing structures that smaller regional producers cannot match, reinforcing its position as the preferred commodity-grade supplier across Asian and export markets. The September 2024 capacity expansion at the Hebei facility, which added approximately 15% incremental annual production volume, signals continued capital commitment to defending this market position through volume leadership rather than margin expansion.

DSM-Firmenich and BASF SE represent the market's two most significant multinational incumbents, each leveraging global distribution networks, multi-market regulatory certifications, and diversified nutritional ingredient portfolios that enable bundled ingredient selling to large food and pharmaceutical manufacturers. DSM-Firmenich's 2023 merger substantially expanded its functional nutrition customer access, and its premium methylcobalamin VALIDA offering with expanded production capacity added in April 2025 at its Sisseln, Switzerland facility positions the company to capture disproportionate margin in the fastest-growing product tier. The strategic logic is straightforward: as pricing pressure from Chinese producers intensifies in commodity cyanocobalamin, the highest returns accrue to companies with credible premium-tier product lines and the regulatory infrastructure to service pharmaceutical and clinical-grade buyers. BASF SE's Performance Products division maintains a vertically integrated B12 supply chain with manufacturing in Europe and Asia, supplying pharmaceutical and food-grade material to customers across more than 60 countries.

EUROAPI and Merck KGaA serve the pharmaceutical-grade segment with high-purity B12 formulations for hospital, clinical, and specialty pharmacy channels. Both companies benefit from established relationships with the European Medicines Agency and national health authorities, creating a regulatory compliance barrier that limits entry by commodity-focused suppliers into clinical-grade tender processes and long-term hospital supply agreements. EUROAPI's July 2024 long-term supply agreement for pharmaceutical-grade hydroxocobalamin with a major European generics manufacturer illustrates how regulatory credibility translates into contractual supply security that commodity producers cannot replicate.

Conversations with procurement directors at six major dietary supplement contract manufacturers in our Q1 2026 expert panel converged on a consistent observation: competitive pressure from Chinese commodity-grade B12 suppliers had intensified over the preceding 18 months, with price reductions of 12–18% on food-grade cyanocobalamin forcing Western and Japanese suppliers to accelerate premiumization strategies prioritizing methylcobalamin, pharmaceutical-grade certification, and supply chain transparency as the principal differentiators in customer retention and new account acquisition. This dynamic is reshaping competitive strategy across the market, with the clearest bifurcation emerging between pure-volume commodity producers operating on thin margins and multi-market certified suppliers capable of commanding premium pricing in regulated and clinical channels.

CSPC Pharmaceutical Group and Ningxia Kingvit Pharmaceutical represent the Chinese domestic-facing competitive tier, combining fermentation cost advantages with growing export capability supported by US FDA Drug Master File filings and EU CEP certifications. CSPC received U.S. FDA acknowledgment of its Vitamin B12 Drug Master File submission in February 2025 a certification milestone that opens access to U.S. pharmaceutical manufacturer procurement and signals the broader upgrade trajectory of Chinese pharmaceutical ingredient manufacturing. Mid-tier players including Rochem International Inc., Farbest Brands, and Spectrum Chemical Mfg. Corp. operate as distributors and specialty repackagers serving niche segments pharmaceutical compounding, laboratory supply, and specialty nutraceutical formulation where volume is lower but margin profiles are structurally more favorable than commodity food fortification channels.

Vitamin B12 Market Companies

Major players operating in the market are: DSM-Firmenich, BASF SE, EUROAPI, Spectrum Chemical Mfg. Corp., Fagron, Merck KGaA, CSPC Pharmaceutical Group, Ningxia Kingvit Pharmaceutical, Rochem International Inc., Loba Chemie Pvt. Ltd., Farbest Brands, Hebei Yuxing Bio-Engineering Co., Ltd., and NOW Foods.

DSM-Firmenich is the product of the 2023 merger between Royal DSM and Firmenich, creating one of the world's largest nutrition and wellness ingredient companies. In Vitamin B12, the company offers both cyanocobalamin and methylcobalamin within its Human Nutrition portfolio, supplying food manufacturers, dietary supplement brands, and pharmaceutical formulators globally. Its VALIDA® methylcobalamin product line specifically targets the premium brain health and cognition supplement channel in North America and Europe, combining clinical positioning with regulatory certifications across FDA, EFSA, and Health Canada frameworks. In April 2025, DSM-Firmenich expanded methylcobalamin production capacity at its Sisseln, Switzerland facility to address growing demand from European functional food manufacturers and premium supplement brands the most direct capital commitment to premium-tier B12 growth among the market's multinational incumbents.

BASF SE operates one of the broadest nutritional ingredient portfolios in the global vitamins market, with Vitamin B12 positioned within its Performance Products division alongside a full B-vitamin range. BASF supplies pharmaceutical-grade and food-grade B12 from manufacturing operations in Europe and Asia, supported by a global sales network covering more than 60 countries. The company's competitive strength lies in supply chain vertical integration and the commercial leverage of multi-nutrient bundle selling to large food, beverage, and pharmaceutical manufacturers an approach that makes BASF a preferred single-source partner for buyers seeking to streamline supplier qualification across multiple active ingredients.

EUROAPI, a publicly traded pharmaceutical API specialist spun off from Sanofi in 2022, focuses on high-purity B12 formulations for European hospital and specialty pharmacy markets. Manufacturing at its Vertolaye (France) and Brindisi (Italy) facilities produces cyanocobalamin and hydroxocobalamin to European Pharmacopoeia standards. EUROAPI's positioning as an independent European API supplier has made it a preferred source for generic pharmaceutical manufacturers seeking supply chain diversification away from Asian producers a strategic dynamic reinforced by its July 2024 long-term supply agreement for pharmaceutical-grade hydroxocobalamin with a major European generics manufacturer.

Merck KGaA supplies B12 compounds through its Healthcare and Life Science divisions for pharmaceutical formulation and laboratory applications. The Neurobion® franchise a widely recognized B-vitamin complex therapeutic represents one of the most commercially established B12-containing products in Asia Pacific and Latin American pharmaceutical markets, and in November 2024 Merck KGaA extended the product line into three new Southeast Asian markets Indonesia, Vietnam, and the Philippines through regional pharmaceutical distribution partnerships, broadening geographic revenue exposure in the Vitamin B12 market's fastest-growing end-use region.

CSPC Pharmaceutical Group is among China's leading pharmaceutical manufacturers, with an established API base that includes both cyanocobalamin and methylcobalamin. The company's receipt of U.S. FDA acknowledgment for its Vitamin B12 Drug Master File submission for cyanocobalamin injectable API in February 2025 enables commercial supply to U.S. pharmaceutical manufacturers a market entry milestone that reflects the broader upgrade trajectory of Chinese pharmaceutical ingredient manufacturing toward regulated international markets.

Ningxia Kingvit Pharmaceutical is a specialty Vitamin B12 manufacturer based in the Ningxia Hui Autonomous Region, with dedicated capacity for pharmaceutical-grade and feed-grade B12. Its competitive cost structure and expanding GMP certifications have made it a significant supplier to the Asian animal nutrition market, where consistent, cost-effective B12 supply is a procurement priority for commercial poultry and swine producers operating at industrial scale.

Hebei Yuxing Bio-Engineering Co., Ltd., the current global market leader at an estimated 18% share, operates large-scale microbial fermentation facilities in Hebei province with the sector's most cost-competitive production economics for food-grade cyanocobalamin. Its customer base spans food fortification ingredient buyers, supplement contract manufacturers, and export trading companies across Asia, Europe, and North America. The completion of a fermentation capacity expansion in September 2024, adding approximately 15% incremental annual production volume, reinforces the company's commitment to volume-based competitive positioning in the global commodity-grade B12 segment.

Fagron is a global pharmaceutical compounding specialist that sources B12 as a primary active ingredient for its hospital and pharmacy compounding operations. Its focus on serving hospital pharmacies and institutional compounding centers gives it differentiated access to the clinical injectable B12 segment without direct competition in the consumer supplement or food fortification channels a positioning that insulates the company from the commodity pricing dynamics affecting broader market participants.

Spectrum Chemical Mfg. Corp. and Loba Chemie Pvt. Ltd. serve the laboratory, research, and specialty compounding markets, supplying high-purity B12 reference standards and reagents to pharmaceutical quality control laboratories, academic research institutions, and analytical chemistry applications where certificate-of-analysis documentation and traceability standards are non-negotiable procurement requirements.

Farbest Brands operates as a nutritional ingredient distributor in North America, with B12 both cyanocobalamin and methylcobalamin as part of its broader vitamin and mineral portfolio serving dietary supplement manufacturers and functional food processors. Rochem International Inc. distributes pharmaceutical and nutritional ingredients across North American markets, serving pharmaceutical manufacturers, nutraceutical brands, and food processors with sourcing of regulatory-compliant B12 from established global suppliers.

NOW Foods represents the consumer-facing tier of the competitive landscape. As a vertically integrated dietary supplement company, NOW Foods manufactures and markets multiple B12 product formats including cyanocobalamin tablets, methylcobalamin sublingual lozenges, and liquid B12 formulations under its own brand directly to end consumers through retail health food chains and e-commerce channels, competing on value positioning within the premium natural supplement category and maintaining direct visibility into consumer demand trends that purely B2B ingredient suppliers lack.

Vitamin B12 Industry News

• Apr 2025: DSM-Firmenich expanded methylcobalamin production capacity at its Sisseln, Switzerland nutritional ingredients facility to address growing demand from European functional food manufacturers and premium supplement brands.
• Feb 2025: CSPC Pharmaceutical Group received U.S. FDA acknowledgment of its Vitamin B12 Drug Master File submission for cyanocobalamin injectable API, enabling commercial supply to U.S. pharmaceutical manufacturers.
• Nov 2024: Merck KGaA announced the extension of its Neurobion® Vitamin B12 product line into three new Southeast Asian markets Indonesia, Vietnam, and the Philippines through regional pharmaceutical distribution partnerships.
• Sep 2024: Hebei Yuxing Bio-Engineering Co., Ltd. completed a fermentation capacity expansion at its Hebei facility, adding approximately 15% incremental annual production volume for food-grade cyanocobalamin to meet growing export and domestic fortification demand.

Market Concentration Score

The Vitamin B12 market scores 7 out of 10 on the market concentration scale, reflecting the top five companies' combined 68% revenue share led by a single player at 18%, partially offset by a fragmented long tail of mid-tier distributors and regional manufacturers that sustains pricing competition in commodity-grade segments.

The Vitamin B12 market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Billion) & volume (Kilo Tons) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Cyanocobalamin
  • 0.1% Spray Dried
  • 1% Spray Dried
  • Crystalline Powder
• Methylcobalamin
  • Pharmaceutical Grade
  • Supplement Grade
• Adenosylcobalamin (5'-deoxyadenosylcobalamin)
  • Pharmaceutical Grade
  • Supplement Grade
• Hydroxocobalamin
  • Injectable Grade
  • Oral/Supplement Grade

Market, By Application

• Food Fortification
  • Breakfast Cereals
  • Plant-Based Milk & Beverages
  • Bakery Products
  • Staple Foods (Flour, Sugar, Edible Oils)
• Dietary Supplements
  • Multivitamin/Mineral Supplements
  • B-Complex Supplements
  • Single-Ingredient B12 Supplements
  • Prenatal & Postnatal Supplements
• Pharmaceuticals
  • Intramuscular Injections
  • Subcutaneous Injections
  • Oral Tablets & Capsules
  • Sublingual Preparations
  • Intranasal Gels & Sprays
• Animal Feed & Nutrition
  • Poultry Feed
  • Swine Feed
  • Ruminant Feed
  • Aquaculture Feed

 

Market, By Distribution Channel

• Direct Sales (B2B)
• Distributors & Wholesalers
• Retail Channels
• E-commerce & Online Platforms

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• MEA
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa